VLDB 2026 Research / reviewers in the wild / expert
Rachapun Rotrattanadumrong
dblp:441/9246
· DBLP profile ↗
1ranked-venue papers
1as first author
1since 2021 · last 2025
—ORCID · none
Domains — the database's venue-derived domains; a paper can count in several
Artificial intelligence and machine learning · 1 · 1 first-author · 1 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% | |
| Databases, data mining, and information retrieval
1 paper |
Information retrieval · 100% |
Topics — the 2 heaviest of 2, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology
drug discovery |
0.9 | 1 | 2025 | OligoGym: Curated Datasets and Benchmarks for Oligonucleotide Drug Discovery · NeurIPS 2025 |
Information retrieval › evaluation
benchmark dataset |
0.9 | 1 | 2025 | OligoGym: Curated Datasets and Benchmarks for Oligonucleotide Drug Discovery · NeurIPS 2025 |
Methods — techniques the papers use, named apart from their topics
featurization · 1.7deep learning · 1.7classical machine learning · 1.7
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2025 | OligoGym: Curated Datasets and Benchmarks for Oligonucleotide Drug DiscoveryabstractOligonucleotide therapeutics offer great potential to address previously undruggable targets and enable personalized medicine. However, their progress is often hindered by insufficient safety and efficacy profiles. Predictive modeling and machine learning could significantly accelerate oligonucleotide drug discovery by identifying suboptimal compounds early on, but their application in this area lags behind other modalities. A key obstacle to the adoption of machine learning in the field is the scarcity of readily accessible and standardized datasets for model development, as data are often scattered across diverse experiments with inconsistent molecular representations. To overcome this challenge, we introduce OligoGym, a curated collection of standardized, machine learning-ready datasets encompassing various oligonucleotide therapeutic modalities and endpoints. We used OligoGym to benchmark diverse classical and deep learning methods, establishing performance baselines for each dataset across different featurization techniques, model configurations, and splitting strategies. Our work represents a crucial first step in creating a more unified framework for oligonucleotide therapeutic dataset generation and model training. Rachapun Rotrattanadumrong, Carlo De Donno |
NeurIPS | 1 |